X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

Sabina Kaczanowska | Tara Murty | Ahmad Alimadadi | Cristina F Contreras | Caroline Duault | Priyanka B Subrahmanyam | Warren Reynolds | Norma A Gutierrez | Reema Baskar | Catherine J Wu | Franziska Michor | Jennifer Altreuter | Yang Liu | Aashna Jhaveri | Vandon Duong | Hima Anbunathan | Claire Ong | Hua Zhang | Radim Moravec | Joyce Yu | Roshni Biswas | Stephen Van Nostrand | James Lindsay | Mina Pichavant | Elena Sotillo | Donna Bernstein | Amanda Carbonell | Joanne Derdak | Jacquelyn Klicka-Skeels | Julia E Segal | Eva Dombi | Stephanie A Harmon | Baris Turkbey | Bita Sahaf | Sean Bendall | Holden Maecker | Steven L Highfill | David Stroncek | John Glod | Melinda Merchant | Catherine C Hedrick | Crystal L Mackall | Sneha Ramakrishna | Rosandra N Kaplan
Cancer cell | 2024

Chimeric antigen receptor T cells (CAR-Ts) have remarkable efficacy in liquid tumors, but limited responses in solid tumors. We conducted a Phase I trial (NCT02107963) of GD2 CAR-Ts (GD2-CAR.OX40.28.z.iC9), demonstrating feasibility and safety of administration in children and young adults with osteosarcoma and neuroblastoma. Since CAR-T efficacy requires adequate CAR-T expansion, patients were grouped into good or poor expanders across dose levels. Patient samples were evaluated by multi-dimensional proteomic, transcriptomic, and epigenetic analyses. T cell assessments identified naive T cells in pre-treatment apheresis associated with good expansion, and exhausted T cells in CAR-T products with poor expansion. Myeloid cell assessment identified CXCR3+ monocytes in pre-treatment apheresis associated with good expansion. Longitudinal analysis of post-treatment samples identified increased CXCR3- classical monocytes in all groups as CAR-T numbers waned. Together, our data uncover mediators of CAR-T biology and correlates of expansion that could be utilized to advance immunotherapies for solid tumor patients.

Pubmed ID: 38134936 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: U01 CA224766
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM007365
  • Agency: NCI NIH HHS, United States
    Id: F30 CA271797
  • Agency: Intramural NIH HHS, United States
    Id: ZIA BC011334
  • Agency: NCI NIH HHS, United States
    Id: U24 CA224316
  • Agency: NCI NIH HHS, United States
    Id: K08 CA267057
  • Agency: NCI NIH HHS, United States
    Id: U24 CA224331
  • Agency: NCI NIH HHS, United States
    Id: R01 CA202987
  • Agency: Intramural NIH HHS, United States
    Id: ZIA BC011332
  • Agency: NCI NIH HHS, United States
    Id: U24 CA224309

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Hydrocodone Polyclonal Antibody (antibody)

RRID:AB_1090063

This unknown targets Hydrocodone

View all literature mentions

polyclonal anti-Clostridium botulinum D Toxoid (antibody)

RRID:AB_1066238

This polyclonal targets polyclonal anti-Clostridium botulinum D Toxoid

View all literature mentions

Anti-Human CD45RA (HI100)-170Er (antibody)

RRID:AB_2938862

This monoclonal targets CD45RA

View all literature mentions

Purified anti-human CD160 (antibody)

RRID:AB_2074411

This monoclonal targets CD160

View all literature mentions

Anti-Human CD272/BTLA (MIH26)-163Dy (antibody)

RRID:AB_2910546

This monoclonal targets CD272/BTLA

View all literature mentions

Purified anti-human CD25 (antibody)

RRID:AB_2561751

This monoclonal targets CD25

View all literature mentions

Anti-Human CD152/CTLA-4 (14D3) Antibody (antibody)

RRID:AB_2687649

This monoclonal targets CD152/CTLA-4

View all literature mentions

Purified anti-human CD20 (antibody)

RRID:AB_314250

This monoclonal targets CD20

View all literature mentions

Anti-Human CD137/4-1BB (4B4-1)-158Gd (antibody)

RRID:AB_2888927

This monoclonal targets CD137/4-1BB

View all literature mentions

Purified anti-Cleaved PARP (Asp214) Recombinant (antibody)

RRID:AB_2814517

This recombinant monoclonal targets Cleaved PARP

View all literature mentions

Anti-Human CD134/OX40 (ACT35)-150Nd (antibody)

RRID:AB_2938869

This monoclonal targets CD134/OX40

View all literature mentions

Anti-Human CD45 (HI30)-89Y (antibody)

RRID:AB_2938863

This monoclonal targets CD45

View all literature mentions

Purified anti-human CD3 (antibody)

RRID:AB_314056

This monoclonal targets CD3

View all literature mentions

PE anti-human CD66b (antibody)

RRID:AB_2750201

This monoclonal targets CD66b

View all literature mentions

Slan (M-DC8) Antibody, anti-human, FITC (antibody)

RRID:AB_2733608

This monoclonal targets Slan (M-DC8)

View all literature mentions

PE anti-human CD183 (CXCR3) (antibody)

RRID:AB_10962912

This monoclonal targets CD183

View all literature mentions

APC/Cyanine7 anti-human CD16 (antibody)

RRID:AB_2562952

This monoclonal targets CD16

View all literature mentions

CD62L (L-Selectin) (antibody)

RRID:AB_2744441

This monoclonal targets CD62L (L-Selectin)

View all literature mentions

APC anti-human CD4 (antibody)

RRID:AB_2820224

This monoclonal targets CD4

View all literature mentions

PE anti-human CD8 (antibody)

RRID:AB_2616623

This monoclonal targets CD8

View all literature mentions

Purified anti-human CD10 (antibody)

RRID:AB_314913

This monoclonal targets CD10

View all literature mentions

Anti-Human Ki-67-172Yb (antibody)

RRID:AB_2858243

This monoclonal targets Ki67

View all literature mentions

Anti-Human CD152/CTLA-4 (14D3)-170Er (antibody)

RRID:AB_2858238

This monoclonal targets CD152/CTLA-4

View all literature mentions

Anti-Slan (M-DC8)-FITC, human (antibody)

RRID:AB_2660075

This monoclonal targets Slan (M-DC8)

View all literature mentions

Anti-Human CD197/CCR7 (G043H7)-167Er (antibody)

RRID:AB_2858236

This monoclonal targets CD197/CCR7

View all literature mentions

Anti-Human CD16 (3G8)-165Ho (antibody)

RRID:AB_2802109

This monoclonal targets CD16

View all literature mentions

Anti-Human CD15/SSEA-1 (W6D3)-164Dy (antibody)

RRID:AB_2810970

This monoclonal targets CD15/SSEA-1

View all literature mentions

Anti-Human CD357 (621)-159Tb (antibody)

RRID:AB_2858232

This monoclonal targets CD357 (GITR)

View all literature mentions

Purified anti-human CD142 (antibody)

RRID:AB_2564564

This monoclonal targets CD142

View all literature mentions

Purified anti-human CD3 (antibody)

RRID:AB_571927

This monoclonal targets CD3

View all literature mentions

Anti-Human CD123-143Nd (antibody)

RRID:AB_2811081

This monoclonal targets CD123

View all literature mentions

Purified anti-human CD1c (antibody)

RRID:AB_1088996

This monoclonal targets CD1c

View all literature mentions

Purified anti-human CD235ab (antibody)

RRID:AB_314620

This monoclonal targets CD235ab

View all literature mentions

Purified anti-human CD41 (antibody)

RRID:AB_314372

This monoclonal targets CD41

View all literature mentions

Purified anti-human CD45 (antibody)

RRID:AB_314390

This monoclonal targets CD45

View all literature mentions

Purified anti-human HLA-DR (antibody)

RRID:AB_314680

This monoclonal targets HLA-DR

View all literature mentions